奥卡西平联合左乙拉西坦对癫痫患儿实验室指标和不良反应的影响

Effect of oxcarbazepine combined with levetiracetam on laboratory indicators and adverse reactions in children with epilepsy

目的探究奥卡西平结合左乙拉西坦对癫痫患儿实验室指标与不良反应的影响。方法选取焦作市妇幼保健院2021年1月至2022年6月期间收治的106例癫痫患儿为研究对象,根据治疗方式分为A组、B组,各53例,A组应用奥卡西平治疗,B组应用奥卡西平联合左乙拉西坦治疗,比较2组治疗效果、治疗前后脑神经损伤指标[血清神经元特异性烯醇化酶(NSE)、S-100β、高迁移率族蛋白-1(HMGB-1)、Toll样受体4(TLR4)、核因子κB(NF-κB)]、血清炎症因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤细胞坏死因子-α(TNF-α)]、药物不良反应发生率。结果B组治疗有效率为98.1%(52/53),较A组86.8%(46/53)高(P<0.05);治疗前B组NSE、S-100β、HMGB-1、TLR4、NF-κB水平与A组相比差异无统计学意义(P>0.05);治疗后2组NSE、S-100β、HMGB-1、TLR4、NF-κB水平均低于治疗前,且B组均较A组低(P<0.05);治疗前B组hs-CRP、IL-6、TNF-α水平与A组相比差异无统计学意义(P>0.05);治疗后2组hs-CRP、IL-6、TNF-α水平均低于治疗前,且B组均较A组低(P<0.05);B组药物不良反应发生率为7.6%(4/53),与A组5.7%(3/53)相近(P>0.05)。结论对癫痫患儿应用奥卡西平联合左乙拉西坦治疗,可提升治疗效果,减轻其脑神经损伤、降低血清炎症因子水平,且不增加药物不良反应。

Objective To investigate the effect of combination of oxcarbazepine combined with levetiracetam on laboratory indicators and adverse reactions in children with epilepsy.Methods A total of 106 epileptic children in Jiaozuo Maternal and Child Health Hospital from January 2021 to June 2022 were selected as the research object.They were divided into group A and group B based on treatment,with 53 cases in each group.Group A was treated with oxcarbazepine,and group B was treated with oxcarbazepine combined with levetiracetam,compare the treatment effects and brain nerve injury indicators before and after treatment between two groups[serum neuron specific enolase(NSE),S-100β]、High mobility group protein-1(HMGB-1),Toll like receptor 4(TLR4),nuclear factor kB(NF kB),serum inflammatory factors[hypersensitive C-reactive protein(hs CRP),interleukin-6(IL-6),tumor cell necrosis factor-α(TNF-α)],and the incidence of adverse drug reactions.Results The effective rate of treatment in Group B was 98.1%(52/53),which was higher than 86.8%(46/53)in Group A(P<0.05).Before treatment,the levels of NSE,S-100β,HMGB-1,TLR4,and NF-κB in group B were similar to those of Group A(P>0.05);the levels of NSE,S-100β,HMGB-1,TLR4,and NF-κB in two groups were lower than before treatment,and Group B was lower than Group A(P<0.05).Before treatment,the level of hs-CRP,IL-6 and TNF-αGroup B is similar to Group A(P>0.05);after treatment,the level of hs-CRP,IL-6 and TNF-αin two groups were all lower than those before treatment,and group B was lower than those in Group A(P<0.05).The incidence of adverse drug reaction in group B was 7.6%(4/53),which was close to 5.7%(3/53)in group A(P>0.05).Conclusion The application of oxcarbazepine combined with levetiracetam in the treatment of epileptic children can enhance the therapeutic effect,reduce their cerebral nerve damage,reduce the level of serum inflammatory factor,and do not increase the adverse drug reactions.